Lacosamid Intas

Lacosamide, the active ingredient in Lacosamid Intas, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. By modulating neuronal excitability, it helps reduce seizure frequency and improve seizure control.

GNH USA supplies Lacosamid Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across Europe, Asia, Africa and the Americas.

Lacosamid Intas is a sodium channel‑blocking antiepileptic used as adjunctive therapy for focal seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Focal seizures: improves overall seizure control as a supplemental treatment. Epilepsy (partial seizures): contributes to better management of seizure burden in patients with refractory epilepsy.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Cardiac conduction abnormalities such as PR‑interval prolongation - Severe skin reactions, including Stevens‑Johnson syndrome - Suicidal thoughts or behaviors

Renal impairment: monitor renal function and adjust therapy as clinically indicated. Hepatic impairment: use with caution and observe liver function tests. Cardiac disease: evaluate baseline ECG and monitor for conduction changes. Pregnancy: risk unknown; weigh potential benefits against risks before prescribing. Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic effects. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lacosamid Intas may interact with other medications affecting neuronal excitability or cardiac conduction.

Major Interactions (Avoid): - Co‑administration with other sodium‑channel blockers may increase CNS depression risk. - Use with drugs that prolong PR interval (e.g., certain antiarrhythmics) can exacerbate cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inducers may reduce lacosamide plasma concentrations. - Concomitant alcohol use may enhance dizziness and somnolence. - Combination with other antiepileptics may require therapeutic drug monitoring.